AMG-650 CAS 2410796-79-9

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

2410796-79-9

Name

2410796-79-9

Syn­onyms

Val­i­dat­ed by Experts, Val­i­dat­ed by Users, Non-Val­i­­dat­ed, Removed by Users
2-(6-Azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluor-1-piperidinyl)-6-methyl-4-pyrimidinyl]-4-{[(2-hydroxyethyl)sulfonyl]amino}benzamid [Ger­man] [ACD/IUPAC Name]
2-(6-Azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl]-4-{[(2-hydroxyethyl)sulfonyl]amino}benzamide [ACD/IUPAC Name]
2-(6-Azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluoro-1-pipéridinyl)-6-méthyl-4-pyrimidinyl]-4-{[(2-hydroxyéthyl)sulfonyl]amino}benzamide [French] [ACD/IUPAC Name]
Ben­za­mide, 2-(6-azaspiro[2.5]oct-6-yl)-N-[2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl]-4-[[(2-hydroxyethyl)sulfonyl]amino]- [ACD/​Index Name]
2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-4-(2-hydroxyethylsulfonylamino)benzamide
2410796-79-9 [RN]
Sovil­ne­sib

SMILES

CC1=CC(NC(=O)C2=CC=C(C=C2N2CCC3(CC3)CC2)NS(=O)(=O)CCO)=NC(=N1)N1CCC(F)(F)CC1

Std­InChI

InChI=1S/C26H34F2N6O4S/c1-18-16-22(31-24(29-18)34-12-8-26(27,28)9-13-34)30-23(36)20-3-2-19(32-39(37,38)15-14-35)17-21(20)33-10-6-25(4-5-25)7-11-33/h2-3,16-17,32,35H,4-15H2,1H3,(H,29,30,31,36)

Std­InChIKey

KBDGE­JDI­HZD­PHN-UHF­F­­FAOYSA-N

Mol­e­c­u­lar Formula

C₂₆H₃₄F₂N₆O₄S

Mol­e­c­u­lar Weight

564.648

Prop­er­ties

Appear­ance

Sol­id

Struc­ture

Safe­ty Data

Sym­bol

WGK Germany

3

MSDS Download

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our 

Iden­ti­fi­ca­tion Methods

Shelf Life

2 years

Stor­age

Store at -20°C and away from light

Known Appli­ca­tion

AMG 650 is a high­ly effi­cient and selec­tive inhibitor tar­get­ing KIF18A, an over­ex­pressed kinesin motor pro­tein in human can­cers. It selec­tive­ly inhibits KIF18A MT-ATPase motor activ­i­ty, dis­play­ing speci­fici­ty towards var­i­ous kinesin pro­teins. At con­cen­tra­tions affect­ing sen­si­tive tumor cells, AMG 650 has min­i­mal impact on the in vit­ro pro­lif­er­a­tion of human bone mar­row mononu­clear cells (>100 times). In vivo, AMG 650 exhibits low clear­ance, a long half-life, and favor­able oral bioavail­abil­i­ty. Addi­tion­al­ly, when com­bined with the PARP inhibitor ola­parib, AMG 650 enhances anti­cancer activ­i­ty in tumor mod­els with alter­ations in BRCA1 and CCNE1 com­pared to sin­­gle-agent treatment.

Gen­er­al View of Documents

Links

This prod­uct is devel­oped by our R&D com­pa­ny Cam­ing Phar­ma­ceu­ti­cal Lim­it­ed (http://​www​.cam​ing​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.